Quest PharmaTech Inc.

Equities

QPT

CA74836M1068

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 01:29:59 16/05/2024 am IST			5-day change	1st Jan Change
0.02 ^CAD	-20.00%		-20.00%	-63.64%

30/01	Quest PharmaTech Brief: Says Quest has a 42.5% ownership interest in OncoQuest; Adds dividend income will be used by Quest for general corporate purposes	MT
30/01	Quest PharmaTech Brief: Received a cash dividend payment from OncoQuest Inc. of approximately C$685,000	MT

Quest PharmaTech Inc. Approves Appointment of J. Mark Lievonen and Jeffrey Shon as Board of Directors

July 08, 2021 at 02:45 am IST

Quest PharmaTech Inc. at its announced the results of its July 5, 2021 annual general and special meeting of shareholders. The Company elected J. Mark Lievonen, C.M., FCPA, FCA, LLD and Jeffrey Shon, JD as Board of Directors.

Latest news about Quest PharmaTech Inc.

Quest PharmaTech Brief: Says Quest has a 42.5% ownership interest in OncoQuest; Adds dividend income will be used by Quest for general corporate purposes	31/01	MT
Quest PharmaTech Brief: Received a cash dividend payment from OncoQuest Inc. of approximately C$685,000	31/01	MT
Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis	24/01	MT
Quest PharmaTech Inc. Receives Recommendations from the Data Safety Monitoring Board to Discontinue Oregovomab Phase III Clinical Study	24/01	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	14/12	CI
Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	21/23/21	CI
Quest PharmaTech Provided Product Development Update	11/23/11	MT
Quest PharmaTech Inc. Provides Product Development Update	11/23/11	CI
Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2023	29/23/29	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2023	01/23/01	CI
Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	31/23/31	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	19/22/19	CI
Quest PharmaTech Details Bioceltran Interest Sale, Return of Photodynamic Therapy Technology License	29/22/29	MT
Sang Ho Jang acquired unknown minority stake in Bioceltran Co., Ltd from Quest PharmaTech Inc. for CAD 0.3 million.	28/22/28	CI
Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	27/22/27	CI
Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2022	28/22/28	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2022	27/22/27	CI
Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	26/22/26	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021	23/21/23	CI
Quest Pharmatech Inc. Reports Earnings Results for the Second Quarter Ended July 31, 2021	24/21/24	CI
Quest PharmaTech Inc. Approves Appointment of J. Mark Lievonen and Jeffrey Shon as Board of Directors	08/21/08	CI
Quest Pharmatech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2021	23/21/23	CI
Quest Pharmatech Inc. Reports Earnings Results for the Full Year Ended January 31, 2021	31/21/31	CI
Quest PharmaTech Inc.(TSXV:QPT) dropped from S&P/TSX Venture Composite Index	19/21/19	CI
Quest PharmaTech : Provides Update on Asset Transfer Between OncoQuest and OncoQuest Pharmaceuticals	06/21/06	MT

Chart Quest PharmaTech Inc.

Duration

Period

More charts

Company Profile

Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.âs technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.

Sector

Biotechnology & Medical Research

Calendar

28/05/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QUEST PHARMATECH INC.	-63.64%	3.1M
MODERNA, INC.	+29.77%	49.18B
IQVIA HOLDINGS INC.	+1.00%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.71B
BIO-TECHNE CORPORATION	+8.22%	13.26B
MEDPACE HOLDINGS, INC.	+32.41%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.99B

Other Biotechnology & Medical Research